ヌクレオシド逆転写酵素阻害剤は,固有の抗炎症作用を有する
Benjamin J Fowler1, Bradley D Gelfand2, Younghee Kim3
1Department of Ophthalmology and Visual Sciences, University of Kentucky, Lexington, KY 40536, USA. Department of Physiology, University of Kentucky, Lexington, KY 40536, USA.
まとめ
ヌクレオシド逆転写酵素阻害剤 (NRTIs) は,P2X7駆動疾患に再利用されました. これらのHIV薬は,炎症体の活性化を阻害し,地理的縮と炎症のモデルにおいて有効性を示しています.
科学分野:
- 免疫学 免疫学とは
- ウイルス学 ウイルス学 ウイルス学
- オフタルモロジック (眼科)
背景:
- 核酸逆転写酵素阻害剤 (NRTIs) は,ウイルスの複製を阻害する重要なHIV治療法です.
- Alu RNAはP2X7とNLRP3炎症体を活性化させ,年齢関連の黄斑変性の一種である地理的縮で網膜細胞死につながる.
研究 の 目的:
- P2X7誘発性炎症疾患の治療におけるNRTIの可能性を調査する.
- NRTIsが,抗ウイルス活性から独立してNLRP3炎症ゾームの活性化を阻害できるかどうかを判断する.
主な方法:
- Alu RNAによって誘発されたP2X7媒介のNLRP3炎症体活性化のNRTI阻害を評価した.
- 炎症体活性に対する読み出しとして,評価されたカスパース-1活性化.
- 地理性縮,冠状腺新血管化,移植対宿主疾患,不妊肝炎のマウスモデルでNRTIの有効性を試験した.
主要な成果:
- NRTIsは,P2X7媒介のNLRP3炎症体活性化とAlu RNAによって誘発されたカスパース-1分裂を効果的に抑制しました.
- この阻害は,逆転写酵素阻害とは独立して発生した.
- NRTIsは,炎症性疾患の複数の前臨床モデルで治療効果を示した.
結論:
- NRTIsは,P2X7-NLRP3炎症体経路を阻害することによって強力な抗炎症特性を有しています.
- NRTIsの薬物再利用は,地理的縮を含むP2X7駆動の炎症状態の治療のための有望な戦略です.
関連する概念動画
Inhibitors of Viral Protein Synthesis
47
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
47
siRNA - Small Interfering RNAs
19.2K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
19.2K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
832
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
832
Inhibitors of Bacterial DNA Synthesis
97
Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These...
97
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
740
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
740
Drugs for Treatment of Ulcerative Colitis in IBD
684
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
684


